Related Experiment Video
Updated: Jun 19, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
New therapeutic approaches in the management of metastatic renal cell carcinoma
1Department of Urology, General Hospital of Athens "G. Gennimatas", Athens, Greece. igkialas@ath.forthnet.gr
Abstract:
Renal cell carcinoma (RCC) accounts for approximately 2% of all cancers worldwide. For several decades cytokine therapy using either interleukin-2 (IL-2) or interferon -alpha (IFN-alpha) was the only effective treatment available for patients with metastatic RCC. Metastatic RCC represents a chemotherapy- and radiotherapy-resistant tumor with poor prognosis and 5-year survival rate <10%. Over the past few years considerable advances in the understanding of biology and underlying molecular pathways in RCC have resulted in the development of targeted therapies for this disease.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

